Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transarterial Chemoembolization Clear all
Not listed Phase 1 Interventional

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

NCT01721941
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Phase I dose level 1, Phase I Dose level 2, Phase I Dose level 3
Drug
Lead sponsor
Scripps Clinic Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT01011010
View directory record Official record
Conditions
Liver Cancer
Interventions
doxorubicin hydrochloride, mitomycin C, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

NCT00855218
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 23, 2026, 2:48 AM EDT
Withdrawn Phase 3 Interventional

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

NCT01318200
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma
Interventions
Transarterial Chemoembolization, CyberKnife SBRT
Procedure · Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT02507765
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
Other · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Jul 23, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Interventions
Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Completed No phase listed Observational

Can Quantitative MRI After cTACE Help Predict Survival ?

NCT02173119
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
MRI post-TACE
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 23, 2026, 2:48 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

NCT03143270
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HCQ
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jul 23, 2026, 2:48 AM EDT
Not yet recruiting Phase 2 Interventional

Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

NCT07682454
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Interventions
Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
Procedure · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00335829
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, chemotherapy, embolization therapy, hepatic artery infusion
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609
View directory record Official record
Conditions
Clinically Significant Portal Hypertension
Interventions
Placebo, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Chemoembolization for Lung Tumors

NCT04200417
View directory record Official record
Conditions
Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
Interventions
Chemoembolization, Mitomycin C, Lipiodol, Embospheres
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Not applicable Interventional Results available

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Transarterial Chemoembolization, Proton Beam Radiotherapy
Procedure · Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jul 23, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

NCT00816777
View directory record Official record
Conditions
Unresectable Metastatic Colo-rectal Cancer
Interventions
Chemoembolization with irinotecan Bead, Irinotecan
Procedure · Drug
Lead sponsor
Generic Devices Consulting, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 23, 2026, 2:48 AM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead

NCT01259024
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
transarterial chemoembolization using a drug-eluting bead
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

NCT02753881
View directory record Official record
Conditions
Liver Cancer
Interventions
whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 23, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional

TATE Versus TACE in Intermediate Stage HCC

NCT03145558
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Tirapazamine, Doxorubicin
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Irvine, California • Portland, Oregon • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 23, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

NCT03638141
View directory record Official record
Conditions
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 23, 2026, 2:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

NCT05842174
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Hydroxychloroquine, Lipiodol, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 23, 2026, 2:48 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 23, 2026, 2:48 AM EDT